Nitazoxanide (NSC 697855)

For research use only. Not for use in humans.

目录号:S1627 别名: NTZ 中文名称:硝唑尼特

Nitazoxanide (NSC 697855) Chemical Structure

CAS No. 55981-09-4

Nitazoxanide (NSC 697855, NTZ)是一种人工合成的nitrothiazolyl-salicylamide衍生物,是一种抗原虫剂(作用于犬流感病毒,IC50为0.17 到0.21 μM)。Nitazoxanide 可调节自噬并抑制 mTORC1 信号传递。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1072.67 现货
RMB 812.74 现货
RMB 2233.86 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Nitazoxanide (NSC 697855)发表文献5篇:

产品安全说明书

Influenza Virus抑制剂选择性比较

生物活性

产品描述 Nitazoxanide (NSC 697855, NTZ)是一种人工合成的nitrothiazolyl-salicylamide衍生物,是一种抗原虫剂(作用于犬流感病毒,IC50为0.17 到0.21 μM)。Nitazoxanide 可调节自噬并抑制 mTORC1 信号传递。
靶点
PFOR [2]
()
mTORC1 [6]
()
体外研究

在细胞培养物中,Nitazoxanide降低90%以上的寄生虫的生长,没有人和药物相关的细胞毒性迹象。[1] Nitazoxanide是一种新的thiazolide寄生虫驱除剂,显示优异的对多种原生动物和蠕虫的体外活性。[2] Nitazoxanide及其代谢物tizoxanide在体外比甲硝唑对G. intestinalis, E. histolytica和T. vaginalis有更强的活性。[3] Nitazoxanide表现出对HBV和HCV复制的有效抑制。在HCV的复制子含有细胞中,Nitazoxanide使后续用Nitazoxanide加上干扰素处理更为有效,但不增强Nitazoxanide加上2'CmeC的效果。Nitazoxanide诱导几个HBV蛋白(HBsAg和HBeAg的,核心抗原)在2.2.15细胞中产生的减少,但不影响HBV的RNA的转录。[4] Nitazoxanide表现出对E. histolytica的IC50和IC90值分别为0.017 mg/mL和0.776 mg/mL,对G. intestinalis分别使0.004 mg/mL和0.067 mg/mL,对T. vaginalis.分别为0.034 mg/mL和2.046 mg/mL。Nitazoxanide比甲硝唑和丙硫咪唑对溶组织内阿米巴毒性更大。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2(2.2.15) Mki4RY51cX[rcnHsJIF{e2G7 NGfpUWFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJ\XCjdHn0bZMhSiC4aYL1d{Bqdm[nY4Tl[EBqdiCqdX3hckBJ\XCJMjiyMlIvOTVrIHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJIV5fHKjY3XscJVt[XJidnnyZYwhTE6DIH3lZZN2emWmIEK0JIhzeyCjZoTldkBt[XO2IHTvd4UtKEWFNUC9NE4yOs7:TR?= NETHZlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW1N|gyOid-MkG1OVM5OTJ:L3G+
HepG2(2.2.15) NH7GRoJCdnSrdnnyZYwh[XO|YYm= NHv1dGtCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJSlZiaX7m[YN1\WRiaX6gbJVu[W5iSHXwS|IpOi5{LkG1LUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHX4eJJi[2WubIXsZZIhfmm{YXygSG5CKGyndnXsMEBKSzVyPUCuNVLPxE1? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN6M{K3OEc,Ojh|OEOyO|Q9N2F-
Ava5 NFrLZnhCdnSrdnnyZYwh[XO|YYm= NWLrZZNEOyCmYYnz M2XpSWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhEXiCpZX7veJlx\SBzYjDpcoZm[3SnZDDpckBCfmF3IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{YXygdoVxdGmlYYTpc44h[W[2ZYKgN{Bl[Xm|IHL5JIJtd3RiaInidollcXqjdHnvckBidmGueYPpd{whTUN3ME2wMlIy|ryP MnHBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyNUm5PFMoRjJ{MEW5PVg{RC:jPh?=
Huh7.5 MnvmRY51cX[rcnHsJIF{e2G7 NHuxTJA{KGSjeYO= NXXQPHkySW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEOYIHflco91gXCnIEHhJIlv\mWldHXkJIlvKEi3aEeuOUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKHKncHzpZ4F1cW:wIHHmeIVzKDNiZHH5d{BjgSCkbH;0JIh6[nKrZHn6ZZRqd25iYX7hcJl{cXNuIFXDOVA:OC5|M988US=> NHTDT5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC1PVk5Oyd-MkKwOVk6QDN:L3G+
HepG2(2.2.15) NFy4TWlCdnSrdnnyZYwh[XO|YYm= MkTkRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTIVx[XSrdHnzJGIhfmm{dYOgbY5n\WO2ZXSgbY4hcHWvYX6gTIVxTzJqMj6yMlE2MSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDpcpRz[WOnbHz1cIFzKH[rcnHsJGRPSSCvZXHzeZJm\CB{NDDodpMh[W[2ZYKgcIF{fCCmb4PlMEBGSzVyPUCuOVnPxE1? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV3M{ixNkc,OjF3NUO4NVI9N2F-
HepG2(2.2.15) M2i1V2FvfGm4aYLhcEBie3OjeR?= MmrjRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTIVx[XSrdHnzJGIhfmm{dYOgbY5n\WO2ZXSgbY4hcHWvYX6gTIVxTzJqMj6yMlE2MSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDlfJRz[WOnbHz1cIFzKH[rcnHsJGRPSSCvZXHzeZJm\CB{NDDodpMh[W[2ZYKgcIF{fCCmb4PlMEBGSzlyPUCuPFPPxE1? NGP3cGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW1N|gyOid-MkG1OVM5OTJ:L3G+
Ava5 NI\LOI1CdnSrdnnyZYwh[XO|YYm= Mo\yN{Bl[Xm| M{HBOWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhEXiCpZX7veJlx\SBzYjDpcoZm[3SnZDDpckBCfmF3IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{YXygdoVxdGmlYYTpc44h[W[2ZYKgN{Bl[Xm|IHL5JIJtd3RiaInidollcXqjdHnvckBidmGueYPpd{whTUN7ME2wMlk{|ryP M3nXNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEW5PVg{Lz5{MkC1PVk5OzxxYU6=
Huh7.5 NHP3NphCdnSrdnnyZYwh[XO|YYm= MnW1N{Bl[Xm| MWjBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIR3Yh\2Wwb4T5dIUhOWFiaX7m[YN1\WRiaX6gTJVpPy53IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{YXygdoVxdGmlYYTpc44h[W[2ZYKgN{Bl[Xm|IHL5JIJtd3RiaInidollcXqjdHnvckBidmGueYPpd{whTUN7ME2xMlHPxE1? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB3OUm4N{c,OjJyNUm5PFM9N2F-
BHK-21 MWnBcpRqfmm{YXygZZN{[Xl? NVLTXmN6SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhS2ira4Xu[5VvgWFidnnyeZMhODZzMXHUe{Bqdm[nY4Tl[EBqdiCESFutNlEh[2WubIOgZpkhWlRvcWDDVkBidmGueYPpd{whTUN3ME2xMlk3|ryP Mo\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OEm5O|UoRjJ6Nki5PVc2RC:jPh?=
HepG2(2.2.15) NUnJOnkzSW62aY\pdoFtKGG|c3H5 MYDBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDI[ZBifGm2aYOgRkB3cXK3czDpcoZm[3SnZDDpckBpfW2jbjDI[ZBIOih{LkKuNVUqKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIHnueJJi[2WubIXsZZIhfmm{YXygSG5CKG2nYYP1doVlKDJ2IHjyd{Bi\nSncjDsZZN1KGSxc3WsJGVEQTB;Mj6x{txO M3TQT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUWzPFEzLz5{MUW1N|gyOjxxYU6=
HCT8 MYXBcpRqeGG{YYPpeIlkKGG|c3H5 MVK0PEBpenN? NEjROVdCdnSrcHHyZZNqfGmlIHHjeIl3cXS7IHHnZYlve3RiQ4L5dJRwe3CxcnnkbZVuKHCjco\1cUBUWExiaX7m[YN1\WRiaX6gbJVu[W5iSFPUPEBk\WyuczDpcoN2[mG2ZXSg[o9zKDR6IHjyd{BjgSCISWTDM2RCWElic4ThbY5qdmdiYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCHQ{WwQVIvO87:TR?= NIHZ[Vc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2PVU4PSd-Mkm0Olk2PzV:L3G+
Vero E6 NVL3T|Q3TnWwY4Tpc44h[XO|YYm= MmGxOFghcHK| MVLJR|UxKG[xcjDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDTRXJUNUOxVj2yJIlvKHSqZTDW[ZJwKEV4IHPlcIwhdGmwZTDheEA1QCCqIHL5JIludXWwb3\seY9z\XOlZX7j[U1j[XOnZDDhd5NigSBqZHX0[YN1cW6pIITo[UB3cXKjbDDOVEBxem:2ZXnuJIlvKHSqZTDueYNt\XW|IH;mJJRp\SCYZYLvJGU3KGOnbHzzLUwhUUN3ME2yMlgyQDN6zszN MlvwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzJ|NUO4OVkoRjN{M{WzPFU6RC:jPh?=
HCT8 MlvWRY51cXCjcnHzbZRq[yCjc4PhfS=> MnX3OFghcHK| NF\jN41CdnSrcHHyZZNqfGmlIHHjeIl3cXS7IHHnZYlve3RiQ4L5dJRwe3CxcnnkbZVuKHCjco\1cUBDT0ZiaX7m[YN1\WRiaX6gbJVu[W5iSFPUPEBk\WyuczDpcoN2[mG2ZXSg[o9zKDR6IHjyd{BjgSCISWTDM2RCWElic4ThbY5qdmdiYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCHQ{WwQVIvQc7:TR?= NVPhRmRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0Olk2PzVpPkK5OFY6PTd3PD;hQi=>
BHK-21 NFrzTY9CdnSrdnnyZYwh[XO|YYm= M1W5NWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGNpcWu3bnf1cpliKH[rcoXzJIlv\mWldHXkJIlvKEKKSz2yNUBk\WyuczDifUBTXC2zUFPSJIFv[Wy7c3nzMEBGSzVyPUKuPVbPxE1? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6OUm3OUc,Ojh4OEm5O|U9N2F-
U2OS NFXQfFNCdnSrdnnyZYwh[XO|YYm= NIfYNZhCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBEcGmtdX7neY56[SC4aYL1d{Bqdm[nY4Tl[EBqdiCqdX3hckBWOk:VIHPlcIx{KGK7IGLUMZFRS1JiYX7hcJl{cXNuIFXDOVA:Oy5yMd88US=> Mn7TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OEm5O|UoRjJ6Nki5PVc2RC:jPh?=
HCT8 MYDBcpRqeGG{YYPpeIlkKGG|c3H5 NGLDXI9CdnSrcHHyZZNqfGmlIHHjeIl3cXS7IHHnZYlve3RiQ4L5dJRwe3CxcnnkbZVuKHCjco\1cUBqdiCKQ2S4JINmdGy|LDDJR|UxRTNwMkZOwG0> M3zYS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEiwNlgyLz5zNkS4NFI5OTxxYU6=
HCT-8 NUHNNWpvSW62aX3pZ5Jw[mmjbDDhd5NigQ>? NUTST4t1SW62aX3pZ5Jw[mmjbDDhZ5Rqfmm2eTDh[4FqdnO2IFPyfZB1d3Oyb4Lp[Il2dSCyYYL2eY0hcW6oZXP0[YQhcW5iaIXtZY4hUEOWLUigZ4VtdHNuIFnDOVA:Oy56zszN M1nDZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUmxNlgxLz5zOEW5NVI5ODxxYU6=
BHK-21 M17oS2FvfGm4aYLhcEBie3OjeR?= MWfBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDDbIlsfW6pdX75ZUB3cXK3czCwPFEx[lS5IHnu[oVkfGWmIHnuJGJJUy1{MTDj[YxteyCkeTDSWE1yWEOUIHHuZYx6e2m|LDDFR|UxRTRwOUZOwG0> MmPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OEm5O|UoRjJ6Nki5PVc2RC:jPh?=
Vero MYXDfZRwfG:6aXPpeJkh[XO|YYm= NX7WdYtEPDhiaILz MlfJR5l1d3SxeHnjbZR6KGGpYXnud5Qh[W[{aXPhckBoemWnbjDtc45s\XliVnXyc{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliV2PUMVEh[XO|YYmsJGlEPTB;MUCuO|TPxE1? NVzOZ3oyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3PFczQDlpPkKzO|g4Ojh7PD;hQi=>
BHK21 NFK0OYdEgXSxdH;4bYNqfHliYYPzZZk> MVyxOkBpenN? MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBDUEt{MTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiMU[gbJJ{KGK7IFPDT{05KGG|c3H5MEBESzVyPUK1{txO MnX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OEm5O|UoRjJ6Nki5PVc2RC:jPh?=
U2OS MV3DfZRwfG:6aXPpeJkh[XO|YYm= M4LoPFE3KGi{cx?= NYjHdYV{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTKRUzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiMU[gbJJ{KGK7IFPDT{05KGG|c3H5MEBESzVyPUK1{txO MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6OUm3OUc,Ojh4OEm5O|U9N2F-
Ava5 MnrUR5l1d3SxeHnjbZR6KGG|c3H5 M{izR|Mh\GG7cx?= NWO5VlViS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSX[jNTDj[YxteyCjZoTldkA{KGSjeYOgZpkhdmW3dILhcEBz\WRiZInlJIF{e2G7LDDDR|UxRTN3zszN MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB3OUm4N{c,OjJyNUm5PFM9N2F-
Huh7.5 MV\DfZRwfG:6aXPpeJkh[XO|YYm= MkHuN{Bl[Xm| M1\IfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGh2cDdwNTDj[YxteyCjZoTldkA{KGSjeYOgZpkhdmW3dILhcEBz\WRiZInlJIF{e2G7LDDDR|UxRTR7zszN Mlq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyNUm5PFMoRjJ{MEW5PVg{RC:jPh?=
DAOY MVfxTHRUKGG|c3H5 M17VNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| M{PxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 MX\xTHRUKGG|c3H5 NIH2VIhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> NWHhUoN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 NVv5e2xjeUiWUzDhd5NigQ>? M2HORZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| M1;jeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 M3HEV5FJXFNiYYPzZZk> Ml3MdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| M3HHTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 M2DrVJFJXFNiYYPzZZk> M1rJ[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 MUfxTHRUKGG|c3H5 NEDlfYVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 M1fDT5FJXFNiYYPzZZk> NVLUdZZjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> NFm5dGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 NHHpSZJyUFSVIHHzd4F6 NVvrOmJJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 NFu2ZYhyUFSVIHHzd4F6 M1LXc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= NXLUZld[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18 MkW0dWhVWyCjc4PhfS=> NWLBWHhDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= MmnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 NIj6dIRyUFSVIHHzd4F6 NF7IdZNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz MnXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD MXTxTHRUKGG|c3H5 NEXaXZJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? M4fac|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

体内研究

在一个无菌幼猪腹泻模型中,Nitazoxanide(250 mg/kg)口服处理11天后,降低了寄生虫的数量。Nitazoxanide诱导了一个药物相关的腹泻可能影响了它的治疗效果。 [1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 62 mg/mL (201.77 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 307.28
化学式

C12H9N3O5S

CAS号 55981-09-4
储存条件 粉状
溶于溶剂
别名 NTZ

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01529073 Unknown status Drug: Nitazoxanide HCV Coinfection|HIV Infection Juan Macías|Spanish National Health System|Andaluz Health Service February 2012 Phase 2
NCT01197157 Completed Drug: Placebo|Drug: Nitazoxanide Hepatitis C National Liver Institute Egypt September 2010 Phase 2|Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
Tags: 购买Nitazoxanide (NSC 697855) | Nitazoxanide (NSC 697855) ic50 | Nitazoxanide (NSC 697855)价格 | Nitazoxanide (NSC 697855) DMSO溶解度 | 采购Nitazoxanide (NSC 697855) | Nitazoxanide (NSC 697855)生产 | Nitazoxanide (NSC 697855) 小鼠 | Nitazoxanide (NSC 697855)化学结构 | Nitazoxanide (NSC 697855)分子量 | Nitazoxanide (NSC 697855) molecular weight | Nitazoxanide (NSC 697855)说明书 | Nitazoxanide (NSC 697855)供应商 | Nitazoxanide (NSC 697855)体内 | Nitazoxanide (NSC 697855)细胞系 | Nitazoxanide (NSC 697855)浓度 | Nitazoxanide (NSC 697855) nmr | Nitazoxanide (NSC 697855)核磁 | Nitazoxanide (NSC 697855)半数抑制浓度 | Nitazoxanide (NSC 697855)体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID